E-Posters-10034

10034_Strauchon

Pdf Summary

This study aimed to determine if combined carboplatin and paclitaxel therapy for gynecologic cancer is associated with new onset or worsening of urinary incontinence. The study analyzed data non-parametrically and found that there was a significant difference in Incontinence Impact Questionnaire (IIQ) scores at different time points during therapy. There were also statistically significant differences in the severity of symptoms of Stress Urinary Incontinence (SUI) and Urge Urinary Incontinence (UUI) at different time points. The study also compared IIQ and Urogenital Distress Inventory (UDI) scores to the Functional Assessment of Cancer Therapy (FACT) scores, and found positive correlations between them. <br /><br />Overall, the study concluded that there is an association between carboplatin/paclitaxel therapy and worsening urinary symptoms in women with gynecologic cancer. However, the study could not determine if these effects were transient or not due to external factors and practice restructuring. The study suggests that further investigation is needed to determine if patients' urinary symptoms should be managed expectantly or more definitively. <br /><br />Urinary incontinence is estimated to affect up to 34% of women with gynecologic cancer, and treatment for gynecologic cancer is generally not considered a risk factor for urinary incontinence. However, this study suggests that the chemotherapy agents carboplatin and paclitaxel may have untoward effects on bladder function due to their neurotoxicity. The study highlights the need for more research into the association between these chemotherapy agents and urinary complaints.

Keywords

carboplatin

paclitaxel

gynecologic cancer

urinary incontinence

Incontinence Impact Questionnaire

stress urinary incontinence

urge urinary incontinence

Urogenital Distress Inventory

Functional Assessment of Cancer Therapy

chemotherapy agents